MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.
View Top Employees from MBX Biosciences, Inc.Website | http://www.mbxbio.com |
Revenue | $1 million |
Funding | $34.6 million |
Employees | 39 (27 on RocketReach) |
Founded | 2019 |
Address | 11711 N Meridian St Ste 300, Carmel, Indiana 46032, US |
Phone | (317) 989-3100 |
Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Drug Discovery, Business Services, Biotechnology |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies |
Looking for a particular MBX Biosciences, Inc. employee's phone or email?
The MBX Biosciences, Inc. annual revenue was $1 million in 2024.
Richard Bartram is the CFO of MBX Biosciences, Inc..
27 people are employed at MBX Biosciences, Inc..
MBX Biosciences, Inc. is based in Carmel, Indiana.
The NAICS codes for MBX Biosciences, Inc. are [541, 54171, 541714, 54, 5417].
The SIC codes for MBX Biosciences, Inc. are [873, 87].